Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Free Cash Flow (2023 - 2025)

Kura Oncology (KURA) has disclosed Free Cash Flow for 3 consecutive years, with $112.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 58.08% to $112.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$70.7 million, a 152.82% decrease, with the full-year FY2025 number at -$70.7 million, down 152.82% from a year prior.
  • Free Cash Flow was $112.7 million for Q4 2025 at Kura Oncology, up from -$80.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $268.8 million in Q4 2024 to a low of -$80.9 million in Q3 2025.
  • A 3-year average of -$5.2 million and a median of -$35.1 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 883.01% in 2024, then plummeted 86.24% in 2025.
  • Kura Oncology's Free Cash Flow stood at -$34.3 million in 2023, then soared by 883.01% to $268.8 million in 2024, then tumbled by 58.08% to $112.7 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Free Cash Flow are $112.7 million (Q4 2025), -$80.9 million (Q3 2025), and -$30.2 million (Q2 2025).